Navigation Links
Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
Date:9/26/2007

Huge Opportunity Exists for Development of More Effective Therapies That Can Improve Survival, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emergence of cancer vaccines, including drugs from Pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016.

The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's GVAX will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The report also finds that, owing to generic erosion, sales of cytotoxic therapies used in pancreatic cancer -- Eli Lilly's Gemzar, Sanofi-Aventis's Eloxatin/Yakult Honsha's Elplat, Pfizer/Yakult's Campto/Camptosar, Daiichi-Sankyo's Topotecin, and Sanofi-Aventis's Taxotere -- will decline significantly during the next decade.

Although it accounts for only about two percent of all cancers, pancreatic cancer -- one of the most difficult cancers to treat -- is the fourth leading cause of cancer deaths in the United States. As a result, the pancreatic cancer market carries extensive unmet medical need, creating a huge opportunity for the development of more effective therapies that can improve survival.

"In combination with Gemzar, the most promising emerging therapies have failed to improve survival in large-scale, Phase III studies," said Mary Argent-Katwala, Ph.D., director at Decision Resources. "Experts argue that the development model for pancreatic therapies needs to be reviewed, that more effort should be directed at identifying responder subsets at an earlier stage of the disease, and that randomized Phase II studies to identify the most promising drug candidates should be more widely implemented."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Internet video is changing the regulatory landscape
2. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
3. Cancer siRNA Oligo Set Version 1.0
4. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
5. Detection of Mutant K-ras in a Kindred With Hereditary Pancreatic Cancer by DGGE
6. Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
9. NeoClone gets $750K for ovarian cancer detection
10. Quintessence Biosciences advances cancer drug
11. Medical College receives $1.4M cancer grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):